Characterization of anti-orthopoxvirus antibody response in general population and gay men

A team of China-based scientists has recently estimated and compared the levels of anti-mpox and anti-vaccinia antibodies in gay men and the general population. The study is currently available on the medRxiv* preprint server.

Study: Unexpectedly higher levels of naturally occurring anti-Orthopoxvirus neutralizing antibodies are observed among gay men than general adult population. Image Credit: Dotted Yeti/Shutterstock
Study: Unexpectedly higher levels of naturally occurring anti-Orthopoxvirus neutralizing antibodies are observed among gay men than general adult population. Image Credit: Dotted Yeti/Shutterstock

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Background

Mpox is a double-stranded DNA virus belonging to the Orthopoxvirus genus. The virus was initially endemic to Central and West Africa. However, multiple outbreaks have recently been detected in many non-endemic countries worldwide.

Most recent cases have particularly been detected in men who have sex with men (MSM). Unlike previous outbreaks, recent outbreaks exhibit some distinct features, including the faster spread of infection between humans and symptom similarities with other sexually-transmitted infections. These features suggest that special behavioral characteristics might make the virus spread more easily in this particular population.  

Smallpox is a life-threatening infection caused by the variola virus, which also belongs to the same Orthopoxvirus genus. Vaccines developed against smallpox are, thus, expected to provide cross-protection against mpox infection.

Because of the complete eradication of smallpox infection in 1980, routine vaccination was terminated worldwide. Thus, a waning anti-smallpox immunity could serve as a fundamental cause of recent mpox outbreaks.

Although smallpox vaccine-induced antibodies are known to cross-protect against all Orthopoxviruses, recent evidence has indicated that anti-mpox neutralizing antibodies can be detected in people without any previous viral exposure or vaccination. This indicates that smallpox vaccination is not the only source of anti-Orthopoxvirus immunity.

In the current study, scientists have estimated and compared the blood levels of anti-mpox and anti-vaccinia antibodies in MSM and the general population residing in China. They have also compared the antibody responses in people born before and after 1981. In China, the smallpox vaccination ended in 1981.   

Vaccinia is a poxvirus belonging to the Orthopoxvirus genus. The virus is used to produce vaccines against smallpox.     

Study design

A total of 326 MSM and 295 general adults from China participated in the study. People with chronic diseases or active infections were excluded from the study.

Peripheral blood samples were collected from the participants to measure the levels of binding and neutralizing antibodies targeting specific proteins of the mpox virus and vaccinia virus.

Binding antibody response

The binding antibody response measured by ELISA revealed that the levels of anti-vaccinia antibodies are significantly higher among general adults born before 1981 compared to those born after 1981. However, no significant difference in antibody response was observed between MSM and male participants of the general population.

Regarding binding antibodies against mpox virus proteins, a relatively higher response was observed among general adults born before 1981. Considering participants born after 1981, a significantly higher anti-mpox antibody response was observed in the general population than in MSM.

Neutralizing antibody response

The scientists measured the levels of anti-vaccinia neutralizing antibodies with the speculation that the antibodies may provide a cross-reactive neutralizing response against the mpox virus.

The findings revealed that the anti-vaccinia neutralizing response is significantly higher in general adults born before 1981 compared to those born after 1981. Interestingly, the study found that MSM participants born after 1981 have significantly higher anti-vaccinia neutralizing antibody responses compared to their age-matched counterparts in the general population.

The scientists speculated that the anti-mpox immunity observed among study participants might arise from previous exposure to Orthopoxvirus. For confirmation, they determined the association between anti-mpox and anti-vaccinia antibody responses.

The analysis identified a positive correlation between anti-mpox and anti-vaccinia binding antibody responses in general adults born before 1981. However, no such correlation was detected in MSM and general adults born after 1981.

Overall, these observations indicate that the anti-Orthopox immunity observed among study participants born after 1981 might not be associated with previous exposure to Orthopoxvirus.

Study significance

The study identifies well-detected levels of anti-mpox and anti-vaccinia antibody responses in the general population and in MSM. Moreover, the study reveals a higher anti-vaccinia neutralizing response in MSM who did not receive smallpox vaccination.

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2022, December 22). Characterization of anti-orthopoxvirus antibody response in general population and gay men. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20221222/Characterization-of-anti-orthopoxvirus-antibody-response-in-general-population-and-gay-men.aspx.

  • MLA

    Dutta, Sanchari Sinha Dutta. "Characterization of anti-orthopoxvirus antibody response in general population and gay men". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20221222/Characterization-of-anti-orthopoxvirus-antibody-response-in-general-population-and-gay-men.aspx>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "Characterization of anti-orthopoxvirus antibody response in general population and gay men". News-Medical. https://www.news-medical.net/news/20221222/Characterization-of-anti-orthopoxvirus-antibody-response-in-general-population-and-gay-men.aspx. (accessed November 22, 2024).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2022. Characterization of anti-orthopoxvirus antibody response in general population and gay men. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20221222/Characterization-of-anti-orthopoxvirus-antibody-response-in-general-population-and-gay-men.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform